Ninsun Biotech is developing the missing biomarker for immunotherapy decision-making in Non Small Cell Lung Cancer.
While immunotherapy is dramatically improving survival, yet up to 80% of patients fail to respond.
By specifically detecting Cancer Stem Cells directly in tumor tissue through a standard IHC test, NinStem Lung™ aims to identify patients unlikely to respond to immunotherapy, improving outcomes while reducing unnecessary toxicity and healthcare costs.
Entering clinical development toward CE IVDR, NinStem Lung™ is designed to complement PD-L1 testing and help clinicians in their decision to treat.
The company targets a market of more than 400,000 tests annually across Europe and the US.
We predict the right treatment at the right time.